Predictive and Discriminating Three-risk-group Prognostic Scoring System for Staging Hodgkin Lymphomas.
From: Service de Biostatistique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon et Laboratoire Biostatistique Sante, equipe UMR CNRS 5558, Lyon, France.
Cancer
- Publish Date: Jan 2007
- ISSN: 0008-543X
- Volume: 109
- Issue: 2
- Pages: 256-64
- Medium: Print
- Language: English
- Citation (JAMA): Maucort-Boulch Delphine, Djeridane Malika, Roy Pascal, et al. Predictive and Discriminating Three-risk-group Prognostic Scoring System for Staging Hodgkin Lymphomas.. Cancer Jan 2007;109:256-64
Abstract
BACKGROUND: Several 3-stage Ann Arbor classification-derived prognostic systems were constructed since 1980 to identify the prognosis of Hodgkin lymphoma (HL). Modern statistical tools were applied to 955 patients treated between 1981 and 1996 to build a 3-stage prognostic scoring system (PSS). METHODS: Each variable associated with 10-year overall survival (10-year OS) was assigned to 2 (0 or 1) or 3 (0, 1 or 3) values. By summing the values attributed to each variable, 3 stages were defined. 10-year OS, 5-year event-free survival (5-year EFS), and freedom from progression (5-year FFP) rates of the PSS and of other existing systems were then compared. RESULTS: Four variables were associated with 10-year OS: age (<40 = 0, >or=40 = 1), number of involved lymphoid areas (1-2 = 0, 3-4 = 1, >or=5 = 2), visceral disease (no = 0, yes = 1), and systemic symptoms (no = 0, yes = 1). Scores 0 and 1, 2 and 3, and >or=4 were attributed to 59.7%, 30.9%, and 9.4% of the patients who had 10-year OS rates of 93.5, 75.7, and 53.4% and 5-year EFS / 5-year FFP rates of 91.2%/90.3%, 78.1%/76.3%, and 54.1%/52.6%, respectively. The discrimination and prediction abilities of the PSS were better than those of the other systems tested; moreover, the PSS adequately identified the few patients with a worse prognosis without resorting to the International Prognostic Score for advanced stages. The PSS was also highly predictive for 489 patients treated between 1997 and 2002. CONCLUSION: PSS is a useful alternative to the existing prognostic systems for evaluating HL patients.
Mesh Headings (Keywords): Adult, Analysis of Variance, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Female, Follow-Up Studies, Hodgkin Disease, Humans, Male, Middle Aged, Neoplasm Staging, Peripheral Blood Stem Cell Transplantation, Prognosis, Radiotherapy, Reproducibility of Results, Risk Factors, Survival Analysis, Time Factors
Check for Full Text / PubMed Unique Identifier (PMID): 17154164
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.